Compare MP Materials (MP) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MP Materials vs Spyre Therapeutics Inc. Common Stock — how do they compare? MP Materials trades at $39.65 (market cap $7.56B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: MP Materials and Spyre Therapeutics Inc. Common Stock are close in size by market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, MP Materials nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MP Materials for 14 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| MP | SYRE | |
|---|---|---|
Market Cap | $7.56B | $7.52B |
Volume | 5,062,845 | 1,441,031 |
Sector | Basic Materials | Health |
52-Week High | $89.85 | $108.92 |
52-Week Low | $38.10 | $22.18 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | $7.04B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MP Materials (MP) trades at $42.43, down 2.14% today, amid bearish technical signals and mixed fundamentals. The stock shows negative profitability metrics with a -19.85% net income margin and -4.08% ROE, though revenue growth is projected from $224M in 2025 to $305M in 2026. Analyst sentiment remains strongly bullish with 13 buy ratings and a $80.70 consensus price target, representing significant upside potential from current levels despite recent price weakness.
The investment case hinges on MP's strategic position in rare earths production and U.S. government support for domestic supply chains. Key risks include persistent negative cash flow from operations, high valuation multiples (P/S 24.64), and sector volatility. The upcoming Q3 2026 earnings report on November 5 will be critical for validating the company's growth trajectory and path to profitability.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MP Materials
MP Materials mines, refines, and manufactures rare earth materials and magnets in the United States. Its products are used in transportation, energy, robotics, defense, and aerospace applications.
Read more on MP →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
